NASDAQ:OCDX - Ortho Clinical Diagnostics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.95
  • Forecasted Upside: 35.83 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$17.63
+0 (0.00%)

This chart shows the closing price for OCDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ortho Clinical Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCDX

Analyst Price Target is $23.95
▲ +35.83% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Ortho Clinical Diagnostics in the last 3 months. The average price target is $23.95, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 35.83% upside from the last price of $17.63.

This chart shows the closing price for OCDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Ortho Clinical Diagnostics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/17/2022Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
2/17/2022BarclaysLower Price Target$25.00 ➝ $20.00Medium
2/17/2022Evercore ISIUpgradeIn-Line ➝ Outperform$21.00Medium
12/27/2021HC WainwrightDowngradeBuy ➝ Neutral$24.68High
12/24/2021BarclaysDowngradeOverweight ➝ Equal Weight$29.00 ➝ $25.00N/A
10/4/2021CitigroupInitiated CoverageBuy$27.00Low
9/28/2021HC WainwrightReiterated RatingBuy$30.00Low
8/5/2021Credit Suisse GroupInitiated CoverageOutperform$23.00High
8/5/2021JPMorgan Chase & Co.Boost Price TargetOverweight$25.00 ➝ $28.00High
8/5/2021HC WainwrightBoost Price TargetBuy$27.00 ➝ $30.00High
7/13/2021BarclaysBoost Price TargetOverweight$24.00 ➝ $27.00Medium
7/12/2021HC WainwrightReiterated RatingBuy$27.00Medium
5/6/2021Credit Suisse GroupBoost Price TargetOutperform$21.00 ➝ $23.00High
5/6/2021Morgan StanleyBoost Price TargetOverweight$24.00 ➝ $25.00High
3/2/2021BarclaysInitiated CoverageOverweight$24.00Medium
2/22/2021Evercore ISIInitiated CoverageOutperform$26.00High
2/22/2021Wolfe ResearchInitiated CoverageMarket PerformMedium
2/22/2021Piper SandlerInitiated CoverageOverweight$27.00Medium
2/22/2021JPMorgan Chase & Co.Initiated CoverageOverweight$25.00Medium
2/22/2021Morgan StanleyInitiated CoverageOverweight$24.00Medium
2/22/2021UBS GroupInitiated CoverageBuy$23.00Medium
2/22/2021CitigroupInitiated CoverageBuy$20.00Medium
2/22/2021Credit Suisse GroupInitiated CoverageOutperform$21.00Medium
2/22/2021The Goldman Sachs GroupInitiated CoverageBuy$27.00Medium
2/22/2021Bank of AmericaInitiated CoverageBuy$23.00Medium
2/22/2021HC WainwrightInitiated CoverageBuy$27.00Medium
(Data available from 7/5/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/6/2021
  • 6 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/5/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/4/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/6/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/5/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/5/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Ortho Clinical Diagnostics logo
Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.
Read More

Today's Range

Now: $17.63
Low: $17.63
High: $17.63

50 Day Range

MA: $17.56
Low: $16.30
High: $18.04

52 Week Range

Now: $17.63
Low: $16.04
High: $22.99

Volume

610 shs

Average Volume

1,240,588 shs

Market Capitalization

$3.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Ortho Clinical Diagnostics?

The following sell-side analysts have issued reports on Ortho Clinical Diagnostics in the last twelve months: Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., and Morgan Stanley.
View the latest analyst ratings for OCDX.

What is the current price target for Ortho Clinical Diagnostics?

0 Wall Street analysts have set twelve-month price targets for Ortho Clinical Diagnostics in the last year. Their average twelve-month price target is $23.95, suggesting a possible upside of 35.8%.
View the latest price targets for OCDX.

What is the current consensus analyst rating for Ortho Clinical Diagnostics?

Ortho Clinical Diagnostics currently has 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCDX will outperform the market and that investors should add to their positions of Ortho Clinical Diagnostics.
View the latest ratings for OCDX.

How do I contact Ortho Clinical Diagnostics' investor relations team?

Ortho Clinical Diagnostics' physical mailing address is 1001 ROUTE 202, RARITAN NJ, 08869. The company's listed phone number is 908-218-8000 and its investor relations email address is [email protected] The official website for Ortho Clinical Diagnostics is www.orthoclinicaldiagnostics.com. Learn More about contacing Ortho Clinical Diagnostics investor relations.